CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07020221
Title field or adapter rule: {'original_value': 'A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:22.494050+00:00
Published At: 2026-10-23T00:00:00+00:00
Record Updated At: 2026-10-23
Source Retrieved At: 2026-10-31T22:17:25.750886+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Pancreatic Ductal Adenocarcinoma", "Non Small Cell Lung Cancer", "Colorectal Cancer", "Solid Tumor, Adult", "G12D Mutated KRAS"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-23", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT07020221"
protocolSection.identificationModule.officialTitle: "A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['VS-7375 + Carboplatin/Pemetrexed/Pembrolizumab Dose Escalation', 'VS-7375 + Carboplatin/Pemetrexed/Pembrolizumab Dose Expansion', 'VS-7375 + Cetuximab Dose Escalation', 'VS-7375 + Cetuximab Dose Expansion', 'VS-7375 + Defactinib Dose Escalation', 'VS-7375 + Gemcitabine/Nab-Paclitaxel Dose Escalation', 'VS-7375 + Gemcitabine/Nab-Paclitaxel Dose Expansion', 'VS-7375 + Midazolam and Repaglinide Drug-Drug Interaction', 'VS-7375 + Pembrolizumab Dose Escalation', 'VS-7375 Monotherapy Dose Escalation', 'VS-7375 Monotherapy Dose Expansion - NSCLC', 'VS-7375 Monotherapy Dose Expansion - PDAC', 'VS-7375 Monotherapy Dose Expansion - Solid Tumors', 'VS-7375 Serial Biopsy'], 'description': 'VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor.', 'name': 'VS-7375', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['VS-7375 + Cetuximab Dose Escalation', 'VS-7375 + Cetuximab Dose Expansion'], 'description': 'Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR).', 'name': 'Cetuximab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['VS-7375 + Carboplatin/Pemetrexed/Pembrolizumab Dose Escalation', 'VS-7375 + Carboplatin/Pemetrexed/Pembrolizumab Dose Expansion'], 'description': 'A combination therapy regimen used as a first-line treatment for advanced non-squamous non-small cell lung cancer.', 'name': 'Carboplatin + Pemetrexed + Pembrolizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['VS-7375 + Gemcitabine/Nab-Paclitaxel Dose Escalation', 'VS-7375 + Gemcitabine/Nab-Paclitaxel Dose Expansion'], 'description': 'A chemotherapy regimen used for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma.', 'name': 'Gemcitabine + Nab-paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['VS-7375 + Pembrolizumab Dose Escalation'], 'description': 'Immunotherapy used as a first-line treatment for advanced non-squamous non-small cell lung cancer.', 'name': 'Pembrolizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['VS-7375 + Defactinib Dose Escalation'], 'description': 'A potent, selective, reversible inhibitor of focal adhesion kinase that also inhibits proline-rich tyrosine kinase-2', 'name': 'Defactinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['VS-7375 + Midazolam and Repaglinide Drug-Drug Interaction'], 'description': 'A short-acting benzodiazepine CNS depressant that has sedative, anxiolytic, amnesic, and hypnotic effects.', 'name': 'Midazolam', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['VS-7375 + Midazolam and Repaglinide Drug-Drug Interaction'], 'description': 'A rapid-acting insulin secretagogue used to lower postprandial blood glucose in patients with type 2 diabetes mellitus.', 'name': 'Repaglinide', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.